SCHEMBL9033160

SCHEMBL9033160

c1ccc(COc2cn[nH]c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
CYP2C19 P33261 1/20 0.50
PTGS2 P35354 1/20 0.50
SLC6A3 Q01959 1/20 0.50
HIF1A Q16665 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
MAOB P27338 6/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
MAOA P21397 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
P4HTM Q9NXG6 1/20 0.47
ALOX5 P09917 1/20 0.47
PRMT5 O14744 2/20 0.46
BCHE P06276 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11870228 1.00 LMNA (0.50) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL17877722 0.84 TSHR (0.44) LMNACYP1A2PTGS1SLC6A2CYP2C19
Hydrochloric Acid SCHEMBL17869143 0.83 TSHR (0.42) MAOBL3MBTL1MAPTMAOARAB9A
SCHEMBL6257616 0.81 AKT2 (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL13373563 0.81 LMNA (0.50) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL17713692 0.80 APP (0.54) MAOBMAPTRAB9ASMN1; SMN2TDP1
SCHEMBL4051954 0.77 AKT1 (0.54) MAOBMAPTMAOAPRMT5BCHE
SCHEMBL1365650 0.74 L3MBTL1 (0.58) MAOBL3MBTL1MAPTMAOARAB9A
SCHEMBL339813 0.74 LMNA (0.82) LMNACYP1A2PTGS1SLC6A2CYP2C19
Benzylphenylether SCHEMBL61660 0.74 LMNA (0.74) LMNACYP1A2PTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108371662-A A kind of application of five-ring heterocycles miazines compound 中国药科大学 2018-08-07 CN claimed
EP-0483851-B1 Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives MITSUBISHI CHEM CORP (JP) 1996-03-13 EP claimed
EP-0483851-A1 Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives Mitsubishi Chemical Corporation (JP) 1992-05-06 EP claimed
US-20240389593-A1 HETEROCYCLIC COMPOUND AND USE THEREOF KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2024-11-28 US disclosed
EP-4317160-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Kumiai Chemical Industry Co., Ltd. (JP) 2024-02-07 EP disclosed
CN-117098759-A Heterocyclic compounds and their use 组合化学工业株式会社 2023-11-21 CN disclosed
WO-2022210999-A1 HETEROCYCLIC COMPOUND AND USE THEREOF クミアイ化学工業株式会社 2022-10-06 WO disclosed
WO-2021085370-A1 AZOLE DERIVATIVE AND USE THEREOF クミアイ化学工業株式会社 2021-05-06 WO disclosed
CN-108658976-B Novel pyrazolo [4,3-c ] pyridine-4 (5) -ketone Bruton kinase inhibitor 南京科技职业学院 2021-02-19 CN disclosed
CN-108371662-A A kind of application of five-ring heterocycles miazines compound 中国药科大学 2018-08-07 CN disclosed
CN-105121444-B Cyano ethyl Pyrazolopyridine ketone as the other than ring type of JANUS kinase inhibitors 默沙东公司 2018-02-16 CN disclosed
EP-3209296-A1 ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-08-30 EP disclosed
CN-107106547-A Ethyl N-Boc piperidinyl pyrazolopyridinones as Janus kinase inhibitors 默沙东公司 2017-08-29 CN disclosed
CN-106029661-A Pyrazolo [1,5-A ] pyridine derivatives and methods of use thereof 亚尼塔公司 2016-10-12 CN disclosed
CN-105121444-A Acyclic cyanoethylpyrazolo pyridones as JANUS kinase inhibitors MERCK SHARP & DOHME 2015-12-02 CN disclosed
US-3979409-A DEHYDROGENATION WITH N-BROMO OR N-CHLORO-SUCCINIMIDE AMERICAN CYANAMID COMPANY (US) 1976-09-07 US disclosed
US-3979409-A DEHYDROGENATION WITH N-BROMO OR N-CHLORO-SUCCINIMIDE AMERICAN CYANAMID COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240389593-A1 HETEROCYCLIC COMPOUND AND USE THEREOF C1S, C3AR1, CBR3 LMNA 2764/4885CYP1A2 300/4885PTGS1 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.